EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Improving CVD risk assessment with eGFR

Sue Lyon

Future Prescriber · 2006

DOI: 10.1002/fps.22 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract A quiet revolution is taking place within the NHS as laboratories grad‐ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com‐munity, affecting health profess‐ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley & Sons, Ltd.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →